Amplia Therapeutics announced today that its lead FAK inhibitor AMP945 has been granted the International Nonproprietary Name (INN) of ‘narmafotinib’.
Commonly referred to as a generic name, an INN is used to identify pharmaceutical substances and active pharmaceutical ingredients.
The process of assigning a name to a drug compound involves an extensive review procedure prior to approval. This review considers similarity to existing drug names, ease of pronunciation across multiple languages, language review for accidental meaning, and finally a period for parties to voice objections regarding the proposed name.
Amplia’s CEO and Managing Director, Dr Chris Burns, commented:
“Approval of the name narmafotinib is an important step in the commercial development of the drug, signaling to potential partners and collaborators our commitment to the long-term development of this exciting agent.”
Read today’s ASX release